BlackRock, Inc. 13D and 13G filings for BioCryst Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale | 2025-03-31 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | BlackRock Inc. BLK | 17,483,490 8.400% | -3,558,982 (-16.91%) | Filing |
| 2024-09-10 12:09 pm Purchase | 2024-08-31 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | BlackRock Inc. BLK | 21,042,472 10.200% | 2,361,102 (+12.64%) | Filing |
| 2024-01-24 5:23 pm Purchase | 2023-12-31 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | BlackRock Inc. BLK | 18,681,370 9.100% | 3,762,415 (+25.22%) | Filing |
| 2023-02-03 4:27 pm Purchase | 2022-12-31 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | BlackRock Inc. BLK | 14,918,955 8.000% | 131,560 (+0.89%) | Filing |
| 2022-02-01 5:08 pm Sale | 2021-12-31 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | BlackRock Inc. BLK | 14,787,395 8.200% | -1,472,350 (-9.06%) | Filing |